Masitinib is a medication that targets cells in our brain and immune system that become overactive in Alzheimer's disease. A clinical trial looked at how masitinib works in people with mild-to-moderate Alzheimer's disease when taken with other Alzheimer's medications.
The clinical trial was double-blind, which means that neither the patients nor the doctors knew who was receiving masitinib and who was receiving a placebo (a fake medication). The trial involved 4 groups of patients, each group receiving either masitinib or a placebo. The patients were aged 50 years or older and had a clinical diagnosis of mild-to-moderate Alzheimer's disease.
The trial had multiple primary outcomes, which means that the researchers were looking at multiple aspects of the patients' health to see if masitinib was effective. The first primary outcome was a test called the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog), which measures a patient's cognitive abilities, such as memory, language, and orientation. The second primary outcome was a test called the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL), which measures a patient's ability to perform daily activities, such as bathing, dressing, and using the toilet.
The results of the trial showed that patients who took masitinib (at a dose of 4.5 mg/kg/day) showed a significant improvement in their cognitive abilities, as measured by the ADAS-cog test, compared to patients who took a placebo. Patients who took masitinib also showed a significant improvement in their ability to perform daily activities, as measured by the ADCS-ADL test, compared to patients who took a placebo. The improvement was seen when compared to their own baseline levels. The trial concluded that masitinib may be helpful in treating mild-to-moderate Alzheimer's disease.